# First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

> **NCT05749900** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yonsei University** · enrollment: 44 (estimated)

## Conditions studied

- HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer

## Interventions

- **DRUG:** Trastuzumab+Nivolumab+Gemcitabine+Cisplatin

## Key facts

- **NCT ID:** NCT05749900
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-12
- **Primary completion:** 2026-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749900, "First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05749900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*